RXRA and primary cutaneous T-cell non-Hodgkin lymphoma: Retinoid-X-receptor alpha (RXRA) ligand bexarotene in combination with chemotherapy was more effective associated with better survival, and improved response in refractory cutaneous T-cell lymphoma (CTCL) (Duvic et al., 2001a; Duvic et al., 2001b; Pileri et al., 2013), metastatic breast cancer (Esteva et al., 2003; Yen et al., 2004; Yen and Lamph, 2005) and non-small cell lung carcinoma (NSCLC) (Khuri et al., 2001; Edelman et al., 2005).